Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.57 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 6/20 | 0.53 |
| ▸ | LCK | P06239 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.50 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405490 | 0.88 | BRAF (0.49) | CSF1RLCKBRAFEGFRABL1 | |
| SCHEMBL4700588 | 0.85 | MAPK1 (0.58) | MAPK14HSPB1CSF1RLCKBRAF | |
| SCHEMBL4701747 | 0.85 | MAPK14 (0.56) | MAPK14HSPB1BRAFSUCNR1 | |
| SCHEMBL5641887 | 0.84 | MAPK14 (0.68) | MAPK14HSPB1CSF1RLCKEGFR | |
| SCHEMBL4700691 | 0.82 | MAPK14 (0.65) | MAPK14HSPB1CSF1RLCKEGFR | |
| SCHEMBL5643247 | 0.81 | MAPK14 (0.63) | MAPK14HSPB1CSF1RLCKEGFR | |
| SCHEMBL4703449 | 0.80 | MAPK14 (0.67) | MAPK14HSPB1LCKKIT | |
| SCHEMBL5106114 | 0.79 | MAPK14 (0.57) | MAPK14HSPB1BRAFSUCNR1 | |
| SCHEMBL2349949 | 0.77 | MAPK14 (0.57) | MAPK14HSPB1ABL1SUCNR1 | |
| SCHEMBL5376317 | 0.76 | MAPK14 (0.66) | MAPK14HSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436272-B1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | claimed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | claimed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | claimed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | claimed |
| EP-1436272-B1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-7309800-B2 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-7151118-B2 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-27 | — | — | US | disclosed |
| EP-1436272-A1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033483-A1 | BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105860-A1 | Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 6/4885HSPB1 744/4885CSF1R 1973/4885 |
| US-20050020540-A1 | Biphenylcarboxylic amide derivatives as p38-kinase inhibitors | MAPK1, MAPKAPK2, MAP3K1 | MAPK14 32/4885HSPB1 690/4885CSF1R 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.